Lv55
1580 积分 2023-10-16 加入
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
23小时前
待确认
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
1天前
待确认
Reflections on FDA Draft Guidance on Bayesian Methods in Trials—Protecting Scientific Integrity and Evidentiary Standards
3天前
求助中
A rank-based approach to improve the efficiency of inferential seamless phase 2/3 clinical trials with dose optimization
14天前
已完结
Effectiveness of maternal immunisation with a three-component acellular pertussis vaccine at preventing pertussis in infants in the United States: Post-hoc analysis of a case-control study using Bayesian dynamic borrowing
16天前
已完结
On stepwise MTPs between Holm’s step-down MTP and the max- p -value MTP for co-primary endpoints: A further extension for free
23天前
已完结
Phase III Probability of Success When Early Development Is Based on a Putative Surrogate Endpoint: A Vaccine Efficacy Case Study
24天前
已完结
Sequential Multiple Assignment Randomized Trials Based on Restricted Mean Survival Time
26天前
已完结
Is Progression-Free Survival 2 Ready for Prime Time in US Food and Drug Administration Regulatory Decision Making?
1个月前
已完结
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
1个月前
已完结
皖公网安备34019202002308
